Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical compositions and methods for their use

a technology of compositions and pharmaceuticals, applied in the field of pharmaceutical compositions, can solve the problems of not producing the desired physiological effect, requiring more frequent and higher doses of drugs, etc., and achieve the effect of increasing the bioavailability of mammal cells and increasing the bioavailability

Inactive Publication Date: 2004-11-11
AGOURON PHARMA INC +1
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016] In another aspect of the present invention are provided methods of increasing the bioavailability in a mammal of a first compound which is metabolized by cytochrome P450, comprising administering to said mammal said first compound and a cytochrome P450-inhibiting amount of a compound of formula (i), or a pharmaceutically acceptable salt or solvate thereof, wherein the cytochrome P450 is the 2D6 isoform.

Problems solved by technology

The drug metabolites that result may, in some cases, be inactive in mammals and therefore may not produce a desired physiological effect.
With some drugs, this metabolism by CYP450 enzymes to produce inactive metabolites may be so extensive that the pharmacokinetics of the drug are unfavorable, thereby requiring more frequent and higher doses of the drug than are desirable to achieve a desired physiological effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions and methods for their use
  • Pharmaceutical compositions and methods for their use
  • Pharmaceutical compositions and methods for their use

Examples

Experimental program
Comparison scheme
Effect test

example 2

6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)--6-(2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one

[0206] 21

[0207] The desired product was prepared analogously to example 1, substituting 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-dihydro--pyran-2,4-dione. from Step 4 below, in place of 2-{4-[2-(2-cyclopentyl-4,-6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitr-ile of that example. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.96 (t, 3H, J=7.4 Hz), 1.30-1.58 (br m, 8H), 1.95 (m, 2H), 2.41 (m, 12H), 2.63 (d,1 H, J =17.5 Hz), 3.61 (d, 1H, J=15.8 Hz), 3.72 (d, 1H, J=15.8 Hz), 6.52 (d, 1H, J=8.1 Hz), 6.74 (m, 2H), 6.93 (s, 1H), 8.84 (s,1 H). Anal. Calcd. For C.sub.28H.sub.34N.sub.4O.sub.4.0.5 AcOH: C, 66.90; H, 6.97; N, 10.76. Found: C, 66.89; H, 6.97, N, 10.83.

Step 1: 4-Bromo-2-ethyl-phenol

[0208] 22

[0209] Sodium hydroxide (1.4 g, 35 mmol) and hydrazine monohydrate (2.04 mL, 42 mmol) were added to a solution of 5'...

example 3

1-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-y-lmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl-)-cyclopropanecarbonitrile

[0217] 26

[0218] The desired product was prepared analogously to example 1, substituting 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethy-l]-2-fluoro-phenyl}-cyclopropanecarbonitrile (0.24 g, 0.65 mmol) from Step 3 below, in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2--yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile of that example. Yield: 64 mg, 19%. .sup.1H NMR (CDCl.sub.3) .delta.: 1.25-1.30 (m, 2H), 1.42-1.68 (m, 10H), 1.88-1.93 (m, 2H), 2.30 (p, J=8.59 Hz, 1H), 2.44-2.73 (m, 10H), 4.05 (d, J=3.03 Hz, 2H), 6.76-6.84 (m, 3H), 7.09-7.22 (m, 1H).

Step 1: 1-(4-Bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile

[0219] 27

[0220] To a slurry of sodium hydride (60% dispersion in mineral oil, 0.82 g, 20.6 mmol) in DMF (20 mL) cooled to 0.degree. C. was added a solution of (4-bromo-2-fluoro-...

example 4

2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimid-in-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-m-ethylpropanenitrile

[0225] 30

[0226] The title compound was prepared analogously to Example 1 where 6-Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde from step 2 below was substituted in place of 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyri-midine-2-carbaldehyde in the final step of that example. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.: 1.48-1.71 (m, 8H), 1.76 (s, 6H), 2.00 (m, 2H), 2.06 (s, 1H), 2.10 (s, 1H), 2.38 (m, 1H), 2.39 (s, 3H), 2.68 (m, 2H), 2.81(m, 1H), 4.09 (s, 2H), 6.86 (d, J=12.9 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 7.84 (t, J=8.1 Hz, 1H), 8.63 (s, 1H), 8.70 (s, 1H). MS (ESI): 518.6(M+H.sup.+).

Step 1: Preparation of (6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)metha-nol

[0227] 31

[0228] To a solution of (3-amino-1H-1,2,4-triazol-5-yl)methanol (16.6 g, 87.6 mmol) in acetic acid was added 3-ethoxymethacrolein (10.0 g, 87.6 mmo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
enantiomeric excessaaaaaaaaaa
enantiomeric excessaaaaaaaaaa
enantiomeric excessaaaaaaaaaa
Login to View More

Abstract

The present invention relates to pharmaceutical compositions and to methods for their use in decreasing cytochrome P450 (CYP450) enzyme activity. The present invention also relates to methods of increasing the bioavailability of a compound in a mammal. Additionally, the present invention relates to methods of decreasing the metabolism of certain compounds in a mammal that are metabolized by the cytochrome P450 enzyme. Furthermore, the present invention relates to pharmaceutical compositions comprising at least one compound metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I).

Description

[0001] This application claims priority to U.S. Patent Application Nos. 60 / 449088, filed Feb. 21, 2003, 60 / 472355, filed May 20, 2003, and U.S. Ser. No. 10 / 718337, filed Nov. 19, 2003.[0002] The present invention relates to pharmaceutical compositions and to methods for their use in decreasing cytochrome P450 (CYP450) enzyme activity. The present invention also relates to methods of increasing the bioavailability of a compound in a mammal. Additionally, the present invention relates to methods of decreasing the metabolism of certain compounds in a mammal that are metabolized by the cytochrome P450 enzyme. Furthermore, the present invention relates to pharmaceutical compositions comprising at least one compound metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I).[0003] In mammals, the cytochrome P450 enzyme system comprises over 100 enzymes that modulate various physiological functions. In particular, the CYP4...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4025A61K31/452A61K31/496A61K31/519A61K31/5377A61K31/541A61P31/14C07D263/58C07D285/06C07D309/32C07D405/06C07D405/10C07D405/12C07D405/14C07D407/06C07D407/10C07D407/12C07D409/06C07D409/10C07D413/02C07D413/06C07D413/10C07D413/12C07D413/14C07D417/02C07D417/06C07D417/10C07D417/12C07D471/04C07D473/30C07D473/36C07D487/04C07D495/04C07D513/04
CPCC07D263/58C07D513/04C07D309/32C07D405/06C07D405/10C07D405/12C07D405/14C07D407/06C07D407/10C07D407/12C07D409/06C07D409/10C07D413/06C07D413/10C07D413/12C07D413/14C07D417/06C07D417/10C07D417/12C07D471/04C07D473/30C07D473/36C07D487/04C07D495/04C07D285/06A61P1/16A61P31/14A61P43/00
Inventor BORCHARDT, ALLEN J.DRAGOVICH, PETER SCOTTGONZALEZ, JAVIERLI, HUILINTON, MARIA ANGELICATATLOCK, JOHN HOWARD
Owner AGOURON PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com